Consumer Marketing Briefs: healthcare reform, USC hospitals, Nielsen

Share this article:
In the frenzied days of December, as the Senate scrambled to wrap up its version of healthcare reform legislation, pharmas and advertisers overcame a last-minute effort to add an amendment that would have jacked up the cost of pharma advertising by pulling its deductability, making it 35% more expensive under top corporate marginal tax. Based on a bill authored by Sen. Mark Begich (D-AK), the amendment never made it to the floor.

Ads for USC hospitals borrow from the LA school's sports program with the tagline “Fight On” alongside gritty pics of docs donning scrubs. The billboard, print and banner ads are by Omaha-based Swanson Russell, and are aimed at raising the profile of the hospitals, which USC says are well-regarded in the medical community but not well-known in their community.   

Pharmas were the No. 2 advertising category for the first nine months of 2009, according to Nielsen, spending $3.2 billion and placing behind automotive's $5.3 billion and ahead of fast food's $3 billion.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?